Ireland
--:--IST
Starting soon Not applicable

Transcranial Direct Current Stimulation for Chemotherapy-Related Chronic Pain in Cancer Survivors

NCT07912775 · tracked via the Priya Life Science Spain tracker
Sponsor
Instituto de investigación e innovación biomédica de Cádiz
Phase
Not applicable
Started
2026-11
Last updated
2026-11-03

Condition(s) studied

Chronic PainNeuropathic PainCancer SurvivorsAnxietyDepressionCognitive DysfunctionChemotherapy-Related Chronic Pain

Investigational drug(s) / intervention(s)

Active tDCS with Sternberg taskSham tDCS with Sternberg task

Active tDCS with Sternberg task: Nurostym tES stimulator (Neuro Device Group SA, Poland; CE-marked) with two saline-soaked sponge electrodes. Anode over the primary motor cortex (C3/C4, 10-20 system, contralateral to the most affected side), cathode over the contralateral supraorbital region. 2 mA for 20 minutes with 30-second ramp-up and ramp-down. During each session, the first 10 minutes are at rest and the next 10 minutes are while performing the Sternberg working-memory task. Acute phase and crossover: 5 consecutive daily sessions. Maintenance: 2 sessions per week for up to 2 months.

Sham tDCS with Sternberg task: Same device, electrode placement, and session schedule as active tDCS, with current delivered only during the 30-second ramp-up and ramp-down at the beginning and end of the session to mimic the sensation of active stimulation, without sustained stimulation. Participants also perform the Sternberg working-memory task (10 minutes at rest, then 10 minutes performing the task). 5 consecutive daily sessions in the acute phase.

Study summary

The goal of this clinical trial is to learn if transcranial direct current stimulation (tDCS) combined with a working-memory task can treat chronic pain and related emotional and cognitive problems after chemotherapy in adult cancer survivors. tDCS is a non-invasive and painless technique that uses a very weak electrical current, applied through two small electrodes on the head, to modulate the activity of certain brain areas. The main questions it aims to answer are:

* Does tDCS reduce chronic pain intensity after chemotherapy in cancer survivors?
* Does tDCS also reduce anxiety, depression, and cognitive problems, and improve the regulation of cortisol, a stress-related hormone?
* Are the effects on pain, anxiety, depression, cognitive problems, and cortisol sustained when treatment continues with a maintenance phase of up to 2 months?

Researchers will compare real tDCS to sham (placebo) tDCS, a look-alike procedure that does not deliver effective stimulation, to see if real tDCS works to reduce pain and improve these symptoms.

Participants will:

* Receive real or sham tDCS (assigned by chance) in 5 daily sessions over 1 week. Each session lasts 20 minutes: 10 minutes at rest and 10 minutes while doing a working-memory task
* If they did not respond to sham tDCS, be offered 5 additional daily sessions of real tDCS
* If they respond to treatment, continue with real tDCS twice a week for up to 2 months
* Complete assessments of pain, mood, memory, attention, and quality of life before treatment, after each phase, and during and at the end of the maintenance phase
* Collect saliva samples to measure cortisol

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of breast, prostate, lung, or colorectal cancer. * Presence of chronic pain related to the cancer or its treatment, with a DN4 score ≥ 4 * Refractory to medical treatment for at least two months. * Completion of systemic chemotherapy. * Age ≥ 18 years. * Ability to read, write, and understand the study questionnaires. Exclusion Criteria: * Relevant psychiatric or neurological disorders, such as dementia, psychosis, or epilepsy. * Concomitant disabling medical conditions. * Intracranial metallic implants or pacemakers. * Extensive myocardial ischemia.

Primary outcome measure(s)

  • Change in pain intensity (Visual Analogue Scale, VAS) after the acute phase — Baseline (T0) and after the acute phase at 1 week (T1)
    Change from baseline in pain intensity measured with the Visual Analogue Scale (VAS), comparing active tDCS with sham tDCS. Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate a worse outcome. Responders are defined as participants with a reduction of at least 2 points from baseline.

Trial sites (2)

FacilityCityRegionStatus
Jerez de la Frontera University Hospital Jerez de la Frontera Cadiz
Puerta del Mar University Hospital Cadiz Cádiz

More Instituto de investigación e innovación biomédica de Cádiz trials in Spain

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07912775 on ClinicalTrials.gov ↗ ← All trials in Spain